Eliquis (Apixaban)
Launch:
Eliquis was launched in 2012 by Bristol-Myers Squibb and Pfizer.
Manufacturer:
Bristol-Myers Squibb and Pfizer
Global Sales in 2023:
Eliquis generated approximately $20 billion in global sales in 2023, continuing its dominance in the anticoagulant market.
Why It’s the Best:
Eliquis is an anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat and prevent deep vein thrombosis and pulmonary embolism. Its superior safety profile compared to other anticoagulants, such as warfarin, and its ease of use without the need for regular blood monitoring have made it a preferred choice among clinicians.